Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 2/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1085011 | 0.86 | ALDH1A1 (0.53) | ALDH1A1HTTNPC1GAAKMT2A | |
| SCHEMBL3455711 | 0.80 | ALDH1A1 (0.75) | ALDH1A1HTTNPC1GAAKMT2A | |
| SCHEMBL31329281 | 0.76 | ALDH1A1 (0.97) | ALDH1A1HTTNPC1GAAKMT2A | |
| SCHEMBL12324732 | 0.74 | ALDH1A1 (0.54) | ALDH1A1HTTGAAKMT2ATSHR | |
| SCHEMBL8214262 | 0.72 | ALDH1A1 (0.50) | ALDH1A1HTTNPC1GAAKMT2A | |
| Hydrochloric Acid SCHEMBL4745810 | 0.71 | CYP19A1 (0.47) | ALDH1A1HTTGAAKMT2ATSHR | |
| SCHEMBL2895681 | 0.71 | LMNA (0.47) | ALDH1A1HTTLMNASMN1; SMN2MAPT | |
| SCHEMBL16477703 | 0.68 | ALDH1A1 (0.40) | ALDH1A1HTTNPC1GAAKMT2A | |
| SCHEMBL4766524 | 0.67 | TSHR (0.40) | ALDH1A1HTTKMT2ATSHRSMN1; SMN2 | |
| SCHEMBL21852247 | 0.66 | ALDH1A1 (0.63) | ALDH1A1NPC1GAAKMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048642-A1 | METHODS FOR TREATING COGNITIVE DISORDERS | ALLERGAN, INC. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048642-A1 | METHODS FOR TREATING COGNITIVE DISORDERS | CHAT, SLC18A3, SLC18A2 | ALDH1A1 1852/4885HTT 457/4885NPC1 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.